Halozyme Therapeutics reported 11.35 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
Acadia Pharmaceuticals 10.08 1.53 Mar/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Alnylam Pharmaceuticals 80.04 90.66 Mar/2026
Amarin 91.05 88.3 Jun/2023
Amgen 19.84 5.47 Mar/2026
Baxter International 86 68.9 Dec/2025
Cara Therapeutics 27.77 117.09 Sep/2021
Eli Lilly 40.27 0.06 Mar/2026
Esperion Therapeutics 129.79 129 Dec/2024
Halozyme Therapeutics 11.35 11.8 Mar/2026
Intrexon 7.54 221.44 Dec/2021
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
MannKind 201.15 102.55 Mar/2026
Pfizer 9.32 5.16 Mar/2026
Rigel Pharmaceuticals 8.61 8.4 Mar/2025
United Therapeutics 20.42 3.1 Mar/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023